PT  - JOURNAL ARTICLE
AU  - Videtic, Gregory M.M.
TI  - Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen?
AID  - 10.3949/ccjm.79.s2.07
DP  - 2012 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - S32--S37
VI  - 79
IP  - 5 e-suppl 1
4099  - http://www.ccjm.org/content/79/5_e-suppl_1/S32.short
4100  - http://www.ccjm.org/content/79/5_e-suppl_1/S32.full
SO  - Cleve Clin J Med2012 May 01; 79
AB  - The optimal chemoradiation regimen for patients with locally advanced non–small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a “one size fits all” approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to show value as add-on treatment to chemoradiation.